Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BCPC
BCPC logo

BCPC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
163.540
Open
162.160
VWAP
161.57
Vol
72.64K
Mkt Cap
5.18B
Low
160.320
Amount
11.74M
EV/EBITDA(TTM)
20.20
Total Shares
32.13M
EV
5.28B
EV/OCF(TTM)
23.96
P/S(TTM)
4.95
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Show More

Events Timeline

(ET)
2026-04-30
07:50:00
Balchem Q1 Revenue $270.71M Beats Consensus
select
2026-03-09 (ET)
2026-03-09
08:20:00
Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform
select
2026-02-20 (ET)
2026-02-20
07:20:00
Balchem Reports Q4 Revenue of $263.6M
select
2025-12-22 (ET)
2025-12-22
08:10:00
Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China
select
2025-10-21 (ET)
2025-10-21
07:02:06
Balchem announces Q3 adjusted EPS of $1.35, up from $1.13 a year ago
select
2025-07-31 (ET)
2025-07-31
07:06:10
Balchem reports Q2 adjusted EPS $1.27 vs $1.09 last year
select

News

seekingalpha
9.5
04-30seekingalpha
Balchem Corporation Reports Record Q1 2026 Earnings with Growth Across Segments
  • Record Financial Performance: Balchem Corporation achieved record net sales of $271 million in Q1 2026, reflecting an 8.1% year-over-year increase, indicating strong market demand and significant growth potential across its segments.
  • Adjusted EBITDA Growth: The company reported adjusted EBITDA of $74 million, marking the 27th consecutive quarter of year-over-year growth, showcasing its robust performance and profitability across various market segments.
  • Stable Market Demand: Management highlighted sustained strong demand in Human Nutrition and Health, particularly for VitaCholine, which is expected to drive future revenue growth and brand expansion opportunities.
  • Cost Pressures and Strategic Response: Despite facing significant inflationary pressures, management plans to leverage its global supply chain and implement price increases to mitigate potential margin compression, ensuring profitability in a competitive landscape.
NASDAQ.COM
2.0
04-30NASDAQ.COM
Balchem (BCPC) Q1 2026 Earnings Transcript
seekingalpha
9.5
04-29seekingalpha
Balchem Corporation Q1 Earnings Announcement Scheduled
  • Earnings Release Date: Balchem Corporation is set to announce its Q1 earnings on April 30th before market open, with a consensus EPS estimate of $1.33, reflecting a 9.0% year-over-year growth, indicating sustained profitability.
  • Revenue Expectations: The expected revenue for Q1 is $266.5 million, representing a 6.4% year-over-year increase, showcasing Balchem's robust market performance and rising product demand.
  • Performance Beat Record: Over the past two years, Balchem has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating consistency in financial performance and strong market confidence.
  • Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward revisions, while revenue estimates have experienced two upward revisions and one downward revision, reflecting analysts' optimistic outlook on Balchem's future performance.
Yahoo Finance
9.5
04-25Yahoo Finance
Balchem Corporation: Stability and Investment Value in Formulation-Embedded Economics
  • Consistent Profitability: Balchem has achieved profitability every year for over fifty years, with 2025 revenue surpassing $1.037 billion for the first time, demonstrating its strong competitive position and stable financial performance in the market.
  • Dividend Growth Record: The company has increased its dividend for 17 consecutive years, with a 10.3% increase in 2025, reflecting management's confidence in future profitability while providing reliable cash flow for investors.
  • Market Positioning Advantage: Balchem's microencapsulation technology has established strong customer relationships in the food and pharmaceutical industries, where the cost of switching suppliers can take months of reformulation and testing, ensuring a recurring revenue stream for the company.
  • Regulatory Protection Effect: The EU's anti-dumping duties on Chinese choline chloride provide structural protection for Balchem's animal nutrition business, expected to last for five years, enhancing its competitiveness in the European market.
Fool
8.5
03-04Fool
Harvey Partners Acquires New Position in Balchem Corporation
  • New Investment Disclosure: Harvey Partners disclosed a new position in Balchem Corporation by acquiring 116,000 shares worth $17.79 million in Q4 2026, indicating confidence in the company's growth potential.
  • Holding Proportion Analysis: This acquisition positions Balchem to represent 1.6% of Harvey Partners' reportable AUM of $1.13 billion, highlighting its significance within the fund's portfolio.
  • Strong Financial Performance: Balchem achieved record net sales of $1 billion in 2025, an 8.8% increase year-over-year, with net income rising to $154.85 million, up 20.5%, showcasing robust performance in the nutrition and health sectors.
  • Solid Financial Position: With a cash balance of $74.6 million and a net debt leverage of only 0.3 times adjusted EBITDA, Balchem's management repurchased $107.6 million in stock in 2025, further boosting investor confidence.
seekingalpha
9.5
02-20seekingalpha
Balchem Corporation Reports Record Q4 2025 Earnings and Growth
  • Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
  • Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
  • International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
  • Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.

Valuation Metrics

The current forward P/E ratio for Balchem Corp (BCPC.O) is 30.21, compared to its 5-year average forward P/E of 33.04. For a more detailed relative valuation and DCF analysis to assess Balchem Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
33.04
Current PE
30.21
Overvalued PE
36.36
Undervalued PE
29.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.96
Current EV/EBITDA
18.43
Overvalued EV/EBITDA
23.05
Undervalued EV/EBITDA
18.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.87
Current PS
4.50
Overvalued PS
5.48
Undervalued PS
4.25

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

What is the best Helium stock to invest in.
Intellectia · 9 candidates
Market Cap: >= 5.00BIndustry: ChemicalsNet Margin: >= 5.00Pe Ttm: 5 - 45Return On Equity: >= 0.0%Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
LIN logo
LIN
Linde PLC
226.97B
SHW logo
SHW
Sherwin-Williams Co
76.78B
ECL logo
ECL
Ecolab Inc
72.95B
NTR logo
NTR
Nutrien Ltd
36.59B
PPG logo
PPG
PPG Industries Inc
22.02B
SQM logo
SQM
Sociedad Quimica y Minera de Chile SA
21.33B
which stock you will pick for today to buy?
Intellectia · 585 candidates
Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55One Day Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GILD logo
GILD
Gilead Sciences Inc
193.35B
HOFT logo
HOFT
Hooker Furnishings Corp
164.25M
BOKF logo
BOKF
BOK Financial Corp
8.22B
KRNT logo
KRNT
Kornit Digital Ltd
789.81M
MBWM logo
MBWM
Mercantile Bank Corp
923.14M
FITB logo
FITB
Fifth Third Bancorp
59.06B
best stocks to buy call options in now
Intellectia · 159 candidates
Rsi 14: 30 - 70Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00Is Optionable: TrueOption Sentiments: Bullish
Ticker
Name
Market Cap$
top bottom
ILMN logo
ILMN
Illumina Inc
23.30B
VIV logo
VIV
Telefonica Brasil SA
20.77B
GLXY logo
GLXY
Galaxy Digital Inc
12.68B
GIL logo
GIL
Gildan Activewear Inc
12.27B
IAG logo
IAG
IAMGOLD Corp
11.42B
TIGO logo
TIGO
Millicom International Cellular SA
9.96B

Whales Holding BCPC

A
Algert Global LLC
Holding
BCPC
+19.59%
3M Return
C
Crestline Investors Inc.
Holding
BCPC
+12.60%
3M Return
N
Nationwide Fund Advisors
Holding
BCPC
+7.87%
3M Return
W
Wasatch Advisors LP
Holding
BCPC
+5.04%
3M Return
S
Salem Investment Counselors, Inc.
Holding
BCPC
+4.95%
3M Return
C
Conestoga Capital Advisors, LLC
Holding
BCPC
-0.38%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Balchem Corp (BCPC) stock price today?

The current price of BCPC is 160.85 USD — it has decreased -0.17

What is Balchem Corp (BCPC)'s business?

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

What is the price predicton of BCPC Stock?

Wall Street analysts forecast BCPC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCPC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Balchem Corp (BCPC)'s revenue for the last quarter?

Balchem Corp revenue for the last quarter amounts to 270.71M USD, increased 8.06

What is Balchem Corp (BCPC)'s earnings per share (EPS) for the last quarter?

Balchem Corp. EPS for the last quarter amounts to 1.25 USD, increased 10.62

How many employees does Balchem Corp (BCPC). have?

Balchem Corp (BCPC) has 1352 emplpoyees as of May 06 2026.

What is Balchem Corp (BCPC) market cap?

Today BCPC has the market capitalization of 5.18B USD.